A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. It includes a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry, and now over 130 companies are profiled.
A range of dynamic trends are pushing market growth and company valuations.
- personalized medicine;
- liquid biopsy;
- emergence of new economies with large markets;
- and a greater understanding of the role of genetic material in Disease & Health.
Working against this dynamic market are the forces of the COVID Driven Recession. The latest numbers in this report factor in the different COVID forces and their timing, and their effect on growth.
Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.
In addition to customization work, breakouts for particular segments, assistance and support is included free of charge.
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2021 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
Assistance in providing specific growth and market size estimates for new technology tests is provided. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.
The report includes detailed breakouts for 18 Countries and 4 Regions; a detailed breakout for any country in the world is available.
1 Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID-19 Pandemic
2 Guide for Executives, Marketing, Sales and Business Development Staff
3 Guide for Management Consultants and Investment Advisors
4 Introduction and Market Definition
4.1 What is Molecular Diagnostics
4.2 The Diagnostics Revolution
4.3 Market Definition
4.3.1 Revenue Market Size
4.5 U.S. Medical Market and laboratory Testing - Perspective
4.5.1 U.S. Medicare Expenditures for Laboratory Testing
5 Market Overview
5.1 Market Participants
5.1.1 Academic Research Lab
5.1.2 Diagnostic Test Developer
5.1.3 Genomic Instrumentation Supplier
5.1.4 Cell Separation and Viewing Instrumentation Supplier.
5.1.5 Pharmaceutical/Reagent Supplier
5.1.6 Independent Testing Lab
5.1.7 Public National/Regional Lab
5.1.8 Hospital lab
5.1.9 Physician Lab
5.1.10 Audit Bodies
5.1.11 Certification Body
5.2 Market Segments
5.2.1 Traditional Market Segmentation
5.2.2 Laboratory Focus and Segmentation
5.3 Industry Structure
5.3.1 Hospital Testing Share
5.3.2 Economies of Scale
5.3.3 Physician Office Labs
5.3.4 Physicians and POCT
6 Market Trends
6.1 Factors Driving Growth
6.1.1 New Diagnostics Create New Markets
6.1.2 New Roles for Diagnostics
6.1.3 Longevity and Outcomes
6.1.4 Expanding the Pharmaceutical Toolbox
6.1.5 Regulatory Retreat
6.2 Factors Limiting Growth
6.2.1 Falling Prices
6.2.2 Lower Costs
6.2.3 COVID Pandemic
6.2.4 Wellness has a Downside
6.3 Instrumentation and Automation
6.3.1 Instruments Key to Market Share
6.3.2 Bioinformatics Plays a Role
6.4 Diagnostic Technology Development
6.4.1 Next Generation Sequencing
6.4.2 Shifting Role of Diagnostics
6.4.3 Multiplexing and Foundation One
6.4.4 Pharmacogenomics Technology
6.4.5 Whole Genome Sequencing
6.4.6 Gene Editing and Gene Therapy
7 Molecular Diagnostics Recent Developments
7.1 Recent Developments - Importance and How to Use This Section
7.1.1 Importance of These Developments
7.1.2 How to Use This Section
7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx
7.3 Invitae to Acquire Genosity for $200M
7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
7.6 Natera Revenues Grow 35 Percent
7.7 AnchorDx Closes $40M Financing Round
7.8 Exact Sciences Strategy for End-to-End Cancer Testing
7.9 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
7.10 Singlera Genomics Closes $150M Funding for Cancer Screening
7.11 Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform
7.12 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
7.13 Metastatic Cancer Markers Identified in Clinical WGS Study
7.14 Stitch Bio Bets on CRISPR Tech
7.15 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
7.16 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
7.17 Progress, Challenges in Liquid Biopsy Reimbursement
7.18 Israeli Startup Curesponse Raises $6M
7.19 Coronavirus Pandemic Bites into European Cancer Research
7.20 Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
7.21 Combining CRISPR and Nanopore Sequencing
7.22 Liquid Biopsy Detects Cancer Early via Cell Clusters
7.23 Roche, Illumina unveil 15-year cancer diagnostic tie-up
7.24 Saga, Servier Sign Liquid Biopsy Services Deal
7.25 Home urine test could revolutionize diagnosis of prostate cancer
7.26 Cancer Gene Tests Cost-Effective for Breast Cancer Patients
7.27 Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
7.28 OncoCyte to Buy Cancer Testing Company Razor Genomics
7.29 Blood Test May Eliminate Need for Exploratory Surgery
7.30 NGS Cancer Panel Receives New York State Conditional Approval
7.31 Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb
8 Profiles of Key MDx Companies
8.1 10x Genomics, Inc.
8.2 Abbott Diagnostics
8.3 AccuraGen Inc.
8.4 Adaptive Biotechnologies
8.5 Aethlon Medical
8.6 Agena Bioscience, Inc.
8.8 Anchor Dx
8.9 ANGLE plc
8.10 ApoCell, Inc.
8.11 ArcherDx, Inc.
8.12 ARUP Laboratories
8.14 AVIVA Biosciences
8.15 Baylor Miraca Genetics Laboratories
8.16 Beckman Coulter, Inc.
8.17 BGI Genomics Co. Ltd.
8.18 Bioarray Genetics
8.20 Biocept, Inc.
8.21 Biodesix Inc.
8.24 Biolidics Ltd.
8.25 bioMérieux Diagnostics
8.26 Bioneer Corporation
8.27 Bio-Rad Laboratories, Inc.
8.28 Bio-Reference Laboratories
8.32 Boreal Genomics
8.33 Bristol-Myers Squibb
8.34 Cancer Genetics
8.35 Caris Molecular Diagnostics
8.36 CellMax Life
8.37 Cepheid (now Danaher)
8.38 Charles River Laboratories
8.39 Chronix Biomedical
8.41 Clinical Genomics
8.43 Cytolumina Technologies Corp.
8.45 Datar Cancer Genetics Limited
8.46 Diagnologix LLC
8.47 Diasorin S.p.A.
8.48 Enzo Life Sciences, Inc.
8.49 Epic Sciences
8.50 Epigenomics AG
8.51 Eurofins Scientific
8.52 Exosome Diagnostics
8.53 Exosome Sciences
8.54 Fabric Genomics
8.55 Fluidigm Corp
8.56 Fluxion Biosciences
8.57 Foundation Medicine
8.59 FUJIFILM Wako Diagnostics
8.60 GeneFirst Ltd.
8.61 Genetron Health (Beijing) Co. Ltd.
8.62 Genomic Health
8.64 GILUPI Nanomedizin
8.65 Grail, Inc.
8.66 Guardant Health
8.71 Horizon Discovery
8.72 HTG Molecular Diagnostics
8.75 Incell Dx
8.77 Integrated Diagnostics
8.80 Janssen Diagnostics
8.81 MDNA Life SCIENCES, Inc.
8.82 MDx Health
8.83 Menarini Silicon Biosystems
8.84 Millipore Sigma
8.85 Miltenyi Biotec
8.87 miR Scientific
8.88 Molecular MD
8.90 Myriad Genetics/Myriad RBM
8.91 NantHealth, Inc.
8.94 New Oncology
8.95 Novogene Bioinformatics Technology Co. Ltd.
8.98 Ortho Clinical Diagnostics
8.99 Oxford Nanopore Technologies
8.101 Perkin Elmer
8.102 Personal Genome Diagnostics
8.107 Qiagen Gmbh
8.108 Rarecells SAS
8.110 Roche Molecular Diagnostics
8.112 Sense Biodetection.
8.114 Siemens Healthineers
8.115 Silicon Biosystems
8.116 simfo GmbH
8.117 Singlera Genomics Inc.
8.120 Stratos Genomics
8.121 Sysmex Inostics
8.122 Tempus Labs, Inc.
8.123 Thermo Fisher Scientific Inc.
8.124 Thrive Earlier Detection
8.125 Todos Medical
8.128 Vortex Biosciences
9 The Global Market for MDx Cancer
9.1 MDx Cancer - Global Market Overview by Country
9.1.1 Table - Global Market by Country
9.1.2 Chart - Global Market by Country
9.2 Global Market by Cancer Type - Overview
9.2.1 Table - Global Market by Cancer Type
9.2.2 Chart - Global Market by Cancer Type - Base/Final Comparison
9.2.3 Chart - Global Market by Cancer Type - Base Year
9.2.4 Chart - Global Market by Cancer Type - Final Year
9.2.5 Chart - Global Market by Cancer Type - Share by Year
9.2.6 Chart - Global Market by Cancer Type - Segment Growth
9.3 Global Market by Product Type - Overview
9.3.1 Table - Global Market by Product Type
9.3.2 Chart - Global Market by Product Type - Base/Final Comparison
9.3.3 Chart - Global Market by Product Type - Base Year
9.3.4 Chart - Global Market by Product Type - Final Year
9.3.5 Chart - Global Market by Product Type - Share by Year
9.3.6 Chart - Global Market by Product Type - Segment Growth
9.4 Global Market by Place - Overview
9.4.1 Table - Global Market by Place
9.4.2 Chart - Global Market by Place - Base/Final Comparison
9.4.3 Chart - Global Market by Place - Base Year
9.4.4 Chart - Global Market by Place - Final Year
9.4.5 Chart - Global Market by Place - Share by Year
9.4.6 Chart - Global Market by Place - Segment Growth
10. Global Market by Cancer Type
10.1 MDx Breast Cancer
10.1.1 Table Breast Cancer Testing - by Country
10.1.2 Chart - Breast Cancer Testing Growth
10.2 MDx Colorectal Cancer
10.2.1 Table Colorectal Cancer Testing - by Country
10.2.2 Chart - Colorectal Cancer Testing Growth
10.3 MDx Cervical Cancer
10.3.1 Table Cervical Cancer Testing - by Country
10.3.2 Chart - Cervical Cancer Testing Growth
10.4 MDx Lung Cancer
10.4.1 Table Lung Cancer Testing - by Country
10.4.2 Chart - Lung Cancer Testing Growth
10.5 MDx Prostate
10.5.1 Table Prostate Testing - by Country
10.5.2 Chart - Prostate Testing Growth
10.6 MDx Melanoma Cancer
10.6.1 Table Melanoma Cancer Testing - by Country
10.6.2 Chart - Melanoma Cancer Testing Growth
10.7 MDx Blood
10.7.1 Table Blood Testing - by Country
10.7.2 Chart - Blood Testing Growth
10.8 MDx Companion Dx Development
10.8.1 Table Companion Dx Development - by Country
10.8.2 Chart - Companion Dx Development Growth
10.9 MDx Other Cancer
10.9.1 Table Other Cancer Testing - by Country
10.9.2 Chart - Other Cancer Testing Growth
11. Global Market by Product Type
11.1 MDx Instruments
11.1.1 Table Instruments - by Country
11.1.2 Chart - Instruments Growth
11.2 MDx Reagents
11.2.1 Table Reagents - by Country
11.2.2 Chart - Reagents Growth
11.3 MDx Software and Services
11.3.1 Table Software and Services - by Country
11.3.2 Chart - Software and Services Growth
12. Global Market by Place
12.1 MDx Clinical Laboratory
12.1.1 Table Clinical Laboratory - by Country
12.1.2 Chart - Clinical Laboratory Growth
12.2 MDx Pharmaceutical
12.2.1 Table Pharmaceutical - by Country
12.2.2 Chart - Pharmaceutical Growth
12.3 MDx Research
12.3.1 Table Research - by Country
12.3.2 Chart - Research Growth
13 Cancer Treatment and Trials
13.1 FDA Cancer Drug Approvals by Year
13.2 Clinical Trials Started 2010 to 2016
13.3 Prevalence of Cancer Treatments - 2015
14.1 United States Medicare System: January 2021 Clinical Laboratory Fees Schedule
14.2 FDA Approved Human Genetic Tests
14.3 FDA Approved Microbial Tests
14.4 FDA Approved Pharmacogenomics Tests
List of Tables
Table 1 Lab Spending 2014 to 2024
Table 2 Market Players by Type
Table 3 Clinical Laboratory Departments and Segments
Table 4 Laboratory Management Focus - Different Approaches
Table 5 Key Segmentation Variables Going Forward
Table 6 Five Factors Driving Growth
Table 7 Four Factors Limiting Growth
Table 8 Key Diagnostic Laboratory Technology Trends
Table 9 Next Generation Sequencing Technologies - Speed and Cost
Table 10 - Global MDx Cancer Market by Region
Table 11 Global Market by Cancer Type
Table 12 Global Market by Product Type
Table 13 Global Market by Place
Table 14 MDx Breast Cancer by Country
Table 15 MDx Colorectal Cancer by Country
Table 16 Cervical Cancer Testing by Country
Table 17 Lung Cancer Testing by Country
Table 18 Prostate Testing by Country
Table 19 Melanoma Cancer Testing by Country
Table 20 MDx Blood by Country
Table 21 MDx Companion Dx Development by Country
Table 22 MDx Other Cancer Testing by Country
Table 23 MDx Instruments by Country
Table 24 MDx Reagents by Country
Table 25 Software and Services by Country
Table 26 MDx Clinical Laboratory by Country
Table 27 MDx Pharmaceutical by Country
Table 28 Research by Country
Table 29 2021 Clinical Lab Fee Schedule
List of Figures
Figure 1 Clinical Lab Spending 2014 to 2024
Figure 2 Growth in Aging Population
Figure 3 Death Rates from Cancer - USA
Figure 4 Comparing MDx Diagnostic and Traditional Testing
Figure 5 Global Market Shares Base Year
Figure 6 MDx Market by Cancer - Base vs. Final
Figure 7 Cancer Market Base Year
Figure 8 Cancer Market Final Year
Figure 9 MDx Cancer Share by Year
Figure 10 MDx Cancer Segment Growth Rates
Figure 11 MDx Market by Product - Base vs. Final
Figure 12 Product Market Base Year
Figure 13 Product Market Final Year
Figure 14 MDx Product Share by Year
Figure 15 MDx Product Segment Growth Rates
Figure 16 MDx Market by Place - Base vs. Final
Figure 17 Place Market Base Year
Figure 18 Place Market Final Year
Figure 19 MDx Place Share by Year
Figure 20 MDx Place Segment Growth Rates
Figure 21 Breast Cancer Testing Growth
Figure 22 Colorectal Cancer Testing Growth
Figure 23 Cervical Cancer Testing Growth
Figure 24 Lung Cancer Testing Growth
Figure 25 Prostate Testing Growth
Figure 26 Melanoma Cancer Testing Growth
Figure 27 Blood Testing Growth
Figure 28 Companion Dx Development Growth
Figure 29 Other Cancer Testing Growth
Figure 30 Instruments Growth
Figure 31 Reagents Growth
Figure 32 Software and Services Growth
Figure 33 Clinical Laboratory Growth
Figure 34 Pharmaceutical Growth
Figure 35 Research Growth
Figure 36 FDA Cancer Drug Approvals by Year
Figure 37 Clinical Trials for Immunotherapy by Year
Figure 38 Pie Chart of Prevalence of Cancer Treatments
- 10x Genomics, Inc.
- Abbott Diagnostics
- AccuraGen Inc.
- Adaptive Biotechnologies
- Aethlon Medical
- Agena Bioscience, Inc.
- Anchor Dx
- ANGLE plc
- ApoCell, Inc.
- ArcherDx, Inc.
- ARUP Laboratories
- AVIVA Biosciences
- Baylor Miraca Genetics Laboratories
- Beckman Coulter, Inc.
- BGI Genomics Co. Ltd.
- Bio-Rad Laboratories, Inc.
- Bio-Reference Laboratories
- Bioarray Genetics
- Biocept, Inc.
- Biodesix Inc.
- Biolidics Ltd.
- bioMérieux Diagnostics
- Bioneer Corporation
- Boreal Genomics
- Bristol-Myers Squibb
- Cancer Genetics
- Caris Molecular Diagnostics
- CellMax Life
- Cepheid (now Danaher)
- Charles River Laboratories
- Chronix Biomedical
- Clinical Genomics
- Cytolumina Technologies Corp.
- Datar Cancer Genetics Limited
- Diagnologix LLC
- Diasorin S.p.A.
- Enzo Life Sciences, Inc.
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- Exosome Diagnostics
- Exosome Sciences
- Fabric Genomics
- Fluidigm Corp
- Fluxion Biosciences
- Foundation Medicine
- FUJIFILM Wako Diagnostics
- GeneFirst Ltd.
- Genetron Health (Beijing) Co. Ltd.
- Genomic Health
- GILUPI Nanomedizin
- Grail, Inc.
- Guardant Health
- Horizon Discovery
- HTG Molecular Diagnostics
- Incell Dx
- Integrated Diagnostics
- Janssen Diagnostics
- MDNA Life Sciences, Inc.
- MDx Health
- Menarini Silicon Biosystems
- Millipore Sigma
- Miltenyi Biotec
- miR Scientific
- Molecular MD
- Myriad Genetics/Myriad RBM
- NantHealth, Inc.
- New Oncology
- Novogene Bioinformatics Technology Co. Ltd.
- Ortho Clinical Diagnostics
- Oxford Nanopore Technologies
- Perkin Elmer
- Personal Genome Diagnostics
- Qiagen GmbH
- Rarecells SAS
- Roche Molecular Diagnostics
- Sense Biodetection.
- Siemens Healthineers
- Silicon Biosystems
- Simfo GmbH
- Singlera Genomics Inc.
- Stratos Genomics
- Sysmex Inostics
- Tempus Labs, Inc.
- Thermo Fisher Scientific Inc.
- Thrive Earlier Detection
- Todos Medical
- Vortex Biosciences